Patents by Inventor Zhaoxing Meng
Zhaoxing Meng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220251141Abstract: In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.Type: ApplicationFiled: May 21, 2020Publication date: August 11, 2022Inventors: Tao WANG, Li-Qiang SUN, Zhaoxing MENG, Paul SCOLA
-
Patent number: 11175955Abstract: Provided is a network function virtualization system. The system includes a single-domain virtualized network function manager (VNFM), a single-domain virtualized network function (VNF) entity, and a virtualized infrastructure manager (VIM); one or more network function virtualized single-domain orchestrators (NFV-DO), which are in one-to-one correspondence with single-domains. The NFV-DO includes a virtualized network function orchestrator (VNFO), which is configured to manage one or more of the following functions in the single-domain where the VNFO is located: a network service instance, a network service life cycle, VNFM instantiation, VNF instantiation and a VNF life cycle. The above solution can meet requirements for phased evolution implemented by a current NFV system and requirements for cross-border, cross-regional, multi-vendor service provision and multi-layer management.Type: GrantFiled: April 13, 2016Date of Patent: November 16, 2021Assignee: XI'AN ZHONGXING NEW SOFTWARE CO., LTD.Inventors: Zhaoxing Meng, Daigang Xu, Yuhong Xue, Houqiang Xu
-
Patent number: 10745382Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.Type: GrantFiled: October 11, 2016Date of Patent: August 18, 2020Assignee: bristol-myers squibb companyInventors: Kap-Sun Yeung, Timothy P. Connolly, David B. Frennesson, Katharine A. Grant-Young, Piyasena Hewawasam, David R. Langley, Zhaoxing Meng, Eric Mull, Kyle E. Parcella, Mark George Saulnier, Li-Qiang Sun, Alan Xiangdong Wang, Ningning Xu, Juliang Zhu, Paul Michael Scola
-
Patent number: 10590105Abstract: The present disclosure generally relates to compounds of formula (I), wherein R2 is a phenyl or pyridinyl moiety, useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.Type: GrantFiled: July 5, 2017Date of Patent: March 17, 2020Assignee: Bristol-Meyers Squibb CompanyInventors: Kap-Sun Yeung, Katharine A. Grant-Young, Juliang Zhu, Mark G. Saulnier, David B. Frennesson, Zhaoxing Meng, Paul Michael Scola
-
Publication number: 20190185450Abstract: The present disclosure generally relates to compounds of formula (I), wherein R2 is a phenyl or pyridinyl moiety, useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.Type: ApplicationFiled: July 5, 2017Publication date: June 20, 2019Inventors: Kap-Sun YEUNG, Katharine A. Grant-Young, Juliang Zhu, Mark G. Saulnier, David B. Frennesson, Zhaoxing Meng, Paul Michael Scola
-
Patent number: 10144706Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.Type: GrantFiled: August 29, 2017Date of Patent: December 4, 2018Assignee: Bristol-Myers Squibb CompanyInventors: Kap-Sun Yeung, Katharine A. Grant-Young, Juliang Zhu, Mark G. Saulnier, David B. Frennesson, David R. Langley, Piyasena Hewawasam, Tao Wang, Zhongxing Zhang, Zhaoxing Meng, Li-Qiang Sun, Eric Mull, Paul Michael Scola
-
Publication number: 20180307538Abstract: Provided is a network function virtualization system. The system includes a single-domain virtualized network function manager (VNFM), a single-domain virtualized network function (VNF) entity, and a virtualized infrastructure manager (VIM); one or more network function virtualized single-domain orchestrators (NFV-DO), which are in one-to-one correspondence with single-domains. The NFV-DO includes a virtualized network function orchestrator (VNFO), which is configured to manage one or more of the following functions in the single-domain where the VNFO is located: a network service instance, a network service life cycle, VNFM instantiation, VNF instantiation and a VNF life cycle. The above solution can meet requirements for phased evolution implemented by a current NFV system and requirements for cross-border, cross-regional, multi-vendor service provision and multi-layer management.Type: ApplicationFiled: April 13, 2016Publication date: October 25, 2018Inventors: Zhaoxing MENG, Daigang XU, Yuhong XUE, Houqiang XU
-
Publication number: 20180057455Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.Type: ApplicationFiled: August 29, 2017Publication date: March 1, 2018Inventors: KAP-SUN YEUNG, Katharine A. Grant-Young, Juliang Zhu, Mark G. Saulnier, David B. Frennesson, David R. Langley, Piyasena Hewawasam, Tao Wang, Zhongxing Zhang, Zhaoxing Meng, Li-Qiang Sun, Eric Mull, Paul Michael Scola
-
Patent number: 9682980Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various disorders of the central nervous system.Type: GrantFiled: June 19, 2013Date of Patent: June 20, 2017Assignee: Bristol-Myers Squibb CompanyInventors: Ronald J. Mattson, Zhaoxing Meng, Leatte R. Guernon
-
Publication number: 20170107202Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.Type: ApplicationFiled: October 11, 2016Publication date: April 20, 2017Inventors: KAP-SUN YEUNG, Timothy P. Connolly, David B. Frennesson, Katharine A. Grant-Young, Piyasena Hewawasam, David R. Langley, Zhaoxing Meng, Eric Mull, Kyle E. Parcella, Mark George Saulnier, Li-Qiang Sun, Alan Xiangdong Wang, Ningning Xu, Juliang Zhu, Paul Michael Scola
-
Publication number: 20150152113Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various disorders of the central nervous system.Type: ApplicationFiled: June 19, 2013Publication date: June 4, 2015Inventors: Ronald J. Mattson, Zhaoxing Meng, Leatte R. Guernon
-
Patent number: 8765767Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various disorders of the central nervous system.Type: GrantFiled: March 14, 2013Date of Patent: July 1, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Ronald J. Mattson, Zhaoxing Meng
-
Publication number: 20130245042Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various disorders of the central nervous system.Type: ApplicationFiled: March 14, 2013Publication date: September 19, 2013Inventors: Ronald J. Mattson, Zhaoxing Meng
-
Patent number: 7977362Abstract: Disclosed are compounds, pharmaceutical compositions containing the compounds, methods for using the compounds and processes for making the compounds. More specifically, the disclosure relates to alpha-(N-benzenesulfonamido)cycloalkyl compounds that may inhibit one or both of: (i) the functioning of a ?-secretase enzyme; or (ii) the production of ?-amyloid. Such compounds may be beneficial in the treatment of Alzheimer's disease and other conditions. Representative compounds have the following formula I: wherein: A, R1, and R2 are described herein.Type: GrantFiled: March 17, 2010Date of Patent: July 12, 2011Assignee: Bristol-Myers Squibb CompanyInventors: Dalton King, Zhaoxing Meng, Ivar M. McDonald, Richard E. Olson, John E. Macor
-
Publication number: 20100240708Abstract: Disclosed are compounds, pharmaceutical compositions containing the compounds, methods for using the compounds and processes for making the compounds. More specifically, the disclosure relates to alpha-(N-benzenesulfonamido)cycloalkyl compounds that may inhibit one or both of: (i) the functioning of a ?-secretase enzyme; or (ii) the production of ?-amyloid. Such compounds may be beneficial in the treatment of Alzheimer's disease and other conditions. Representative compounds have the following formula I: wherein: A, R1, and R2 are described herein.Type: ApplicationFiled: March 17, 2010Publication date: September 23, 2010Inventors: Dalton King, Zhaoxing Meng, Ivar M. McDonald, Richard E. Olson, John E. Macor
-
Patent number: 7105516Abstract: The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts or solvates thereof and pharmaceutically acceptable formulations comprising said compounds useful for the treatment of premature ejaculation, depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder and substance abuse disorders.Type: GrantFiled: September 15, 2003Date of Patent: September 12, 2006Assignee: Bristol-Myers Squibb CompanyInventors: Derek John Denhart, Jonathan L. Ditta, Dalton King, John E. Macor, Lawrence R. Marcin, Ronald J. Mattson, Zhaoxing Meng
-
Patent number: 7049314Abstract: The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts or solvates thereof and pharmaceutically acceptable formulations comprising said compounds useful for the treatment of premature ejaculation, depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder and substance abuse disorders.Type: GrantFiled: September 15, 2003Date of Patent: May 23, 2006Assignee: Bristol-Myers Squibb CompanyInventors: Dalton King, Jeffrey A. Deskus, John E. Macor, Ronald J. Mattson, Zhaoxing Meng, Charles P. Sloan
-
Publication number: 20050239874Abstract: Disclosed are novel compounds represented by the following structural formula: R—X—Y; and physiologically acceptable salts thereof. R is a tricyclic core of a cannabinoid or substituted cannabinoid. X is a covalent bond, —CH2— or —CHR1—, wherein R1 a C1 to C3 substituted or unsubstituted alkyl group. Y is a heterocyclic ring, a substituted heterocyclic ring, a carbocyclic ring, a substituted carbocyclic ring, a fused bicyclic ring system, a substituted fused bicyclic ring system, a bridged bicyclic ring system, a substituted bridged bicyclic ring system, a bridged tricyclic ring system or a substituted bridged tricyclic ring system. Also disclosed is a method of stimulating a CB1 and/or CB2 receptor in a subject. The method comprises administering to the subject a therapeutically effective amount of R—X—Y.Type: ApplicationFiled: May 12, 2005Publication date: October 27, 2005Applicant: University of ConnecticutInventors: Alexandros Makriyannis, Dai Lu, Atmaram Khanolkar, Zhaoxing Meng
-
Publication number: 20040077705Abstract: The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts or solvates thereof and pharmaceutically acceptable formulations comprising said compounds 1Type: ApplicationFiled: September 15, 2003Publication date: April 22, 2004Inventors: Dalton King, Jeffrey A. Deskus, John E. Macor, Ronald J. Mattson, Zhaoxing Meng, Charles P. Sloan
-
Publication number: 20040063768Abstract: The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts or solvates thereof and pharmaceutically acceptable formulations comprising said compounds 1Type: ApplicationFiled: September 15, 2003Publication date: April 1, 2004Inventors: Derek John Denhart, Jonathan L. Ditta, Dalton King, John E. Macor, Lawrence R. Marcin, Ronald J. Mattson, Zhaoxing Meng